Evidence map›Paper›PMID 26900390›Full record

ArticleEURASIP journal on bioinformatics & systems biology2016

Gene expression analysis supports tumor threshold over 2.0 cm for T-category breast cancer.

Hiroko K Solvang, Arnoldo Frigessi, Fateme Kaveh, Margit L H Riis, Torben Lüders, Ida R K Bukholm, Vessela N Kristensen, Bettina K Andreassen

Abstract read
In one paragraph

Article in EURASIP journal on bioinformatics & systems biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hiroko K SolvangDepartment of Marine Mammals, Institute of Marine Research, C. Sundts Gate 64, Bergen, 5004 Norway.
Arnoldo FrigessiDepartment of Biostatistics, Institute of Basic Medical Science, University of Oslo, Norway and Statistics for Innovation-(sfi)2, Oslo, Norway.
Fateme KavehMedical Genetics Department, Oslo University Hospital (Ullevål), Oslo, Norway.
Margit L H RiisDepartment of Surgery, Akershus University Hospital, Lørenskog, Norway ; Department of Molecular Biology and Laboratory Sciences (EpiGen), Institute of Clinical Medicine, Akershus University Hospital, Lørenskog, Norway.
Torben LüdersDepartment of Surgery, Akershus University Hospital, Lørenskog, Norway ; Department of Molecular Biology and Laboratory Sciences (EpiGen), Institute of Clinical Medicine, Akershus University Hospital, Lørenskog, Norway.
Ida R K BukholmDepartment of Surgery, Akershus University Hospital, Lørenskog, Norway ; Institute of Clinical Medicine, University of Oslo, Norwegian Center of HPH Network, Oslo, Norway.
Vessela N KristensenDepartment of Molecular Biology and Laboratory Sciences (EpiGen), Institute of Clinical Medicine, Akershus University Hospital, Lørenskog, Norway ; Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Bettina K AndreassenCancer Registry of Norway Institute for Population-based Research, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor size, as indicated by the T-category, is known as a strong prognostic indicator for breast cancer. It is common practice to distinguish the T1 and T2 groups at a tumor size of 2.0 cm. We investigated the 2.0-cm rule from a new point of view. Here, we try to find the optimal threshold based on the differences between the gene expression profiles of the T1 and T2 groups (as defined by the threshold). We developed a numerical algorithm to measure the overall differential gene expression between patients with smaller tumors and those with larger tumors among multiple expression datasets from different studies. We confirmed the performance of the proposed algorithm by a simulation study and then applied it to three different studies conducted at two Norwegian hospitals. We found that the maximum difference in gene expression is obtained at a threshold of 2.2-2.4 cm, and we confirmed that the optimum threshold was over 2.0 cm, as indicated by a validation study using five publicly available expression datasets. Furthermore, we observed a significant differentiation between the two threshold groups in terms of time to local recurrence for the Norwegian datasets. In addition, we performed an associated network and canonical pathway analyses for the genes differentially expressed between tumors below and above the given thresholds, 2.0 and 2.4 cm, using the Norwegian datasets. The associated network function illustrated a cellular assembly of the genes for the 2.0-cm threshold: an energy production for the 2.4-cm threshold and an enrichment in lipid metabolism based on the genes in the intersection for the 2.0- and 2.4-cm thresholds.

Indexed as

Breast cancerDifferentially expressedMicroarray dataOptimization algorithmT-categoryTwo-group comparison statistical test

Identifiers

PMID26900390
PMCPMC4746218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.